COVIDROPS™ and COVINHALER® – Indian Startups Seeking Nasal Sprays and Pocket Inhalers for COVID-19 Therapeutics

PUNE, India, January 19, 2022 /PRNewswire/ — As the therapeutic research landscape for COVID-19 continues to evolve, new formats of vaccines and therapies are being developed around the world to support an effective response against the virus. LaBelforte LLP, an Indian startup promoted by a Pune, announced on Wednesday the launch of its special purpose business entities – Covidrops LLP and Covinhaler LLP to facilitate the development of nasal and inhaled immune system-optimizing drug products.

Nasal Sprays & Pocket Inhalers – Needle Free Immunity

With the prevailing unpredictability around the possible emergence of new variants and the particular challenges facing the current generation of vaccines, there is a growing consensus within a section of the scientific fraternity in favor of the adoption of a multi-modal approach with an emphasis on establishing additional methods that may be particularly effective in reducing virus transmission.

“The company’s goal is to primarily facilitate the co-development of nasal sprays and pocket inhalers that are safe and effective aids in COVID-19 prophylaxis and therapy.”
-Dr. Gaurav Raj Chhabra, Founder, LaBelforte, India

the Since the nose and oral cavity are common entry points for the virus, drug products aimed at properly engaging the local immune response at these sites can add a new dimension to the global response to the coronavirus pandemic.

Targeting mucosal and immune barrier optimization

“Our immediate focus is on host-directed therapeutic options that safely and effectively optimize mucosal and barrier immunity by potentiating the body’s own immune system through expression of immunogenic genes,” says, Chhabra, who has been scrutinizing international developments in the category for over 18 months now.

As a first-line barrier to viral entry and viral excretion, intranasal/inhaled drugs enhancing mucosal immunity may offer remarkable advantage in the prevention and control of COVID-19.

Chhabra adds: The delivery formats chosen are deliberately flexible in order to be able to adapt quickly to successive therapeutic formulations. This is all the more important as you are dealing with an actively progressive public health scenario.” Citing regulatory standards and NDA compliances, the company declined to disclose more details about the candidates under consideration.

Scaling as a Bootstrap startup in India

When asked how the company plans to leverage the necessary resources, V.Sanwale, Co-founder and head of business development at LaBelforte Explain : “In During the first phase, we mainly focused on the development of appropriate collaborations, on a global scale, to seek the most promising new candidates in research, to explore a reoriented drug approach and to prepare the groundwork for ownership. intellectual. Then, as we move forward, we might as well opt for strategic alliances in the main pharma industry for a smooth transition from lab to market. »

In accordance with the forward-looking statement on the company’s website, once it has passed all required regulatory approvals and with competent industry alliances in place, it expects to clear grounds to facilitate the launch of its flagship products by the through its special purpose entities – COVIDROPS and COVINHALER® in India by the second quarter of 2022 and parallel explore international markets as well.

About LaBelforte SENCRL

As an integrated, knowledge-driven startup that delivers value-added networking and collaboration solutions for global biosciences and allied industry, LaBelforte strives to occupy a niche space where it serves as a bridge between breakthrough solutions and enterprising industry partners.

Contact for business and media:
https://www.labelforte.com
[email protected]

Photo: https://mma.prnewswire.com/media/1729481/Covidrops_image.jpg

SOURCELaBelforte SENCRL

About Margie Peters

Check Also

Sun Pharma Q1FY23 figures: Exceed expectations, but with room for improvement

Sun Pharma released its Q1FY23 results last Friday with an overall pace – 4.8% revenue, …